Literature DB >> 20102490

Severe hemophilia with mild bleeding phenotype: molecular characterization and global coagulation profile.

E Santagostino1, M E Mancuso, A Tripodi, V Chantarangkul, M Clerici, I Garagiola, P M Mannucci.   

Abstract

BACKGROUND: Patients with severe hemophilia may show very varied bleeding tendencies, and the reasons for this heterogeneous clinical expression are unclear. The factor VIII/FIX genotype is the main determinant of the residual factor activity; however, different bleeding phenotypes have also been reported in patients sharing the same mutation. Such global coagulation tests as thrombin generation assays are tools with which to investigate different coagulation profiles among severe hemophiliacs. OBJECTIVES, PATIENTS AND METHODS: This case-control study was aimed at comprehensively evaluating the role of genotype and endogenous thrombin potential (ETP) as predictors of the clinical phenotype in severe hemophiliacs with an extremely mild bleeding tendency (cases, n = 22), in comparison with those showing a typical bleeding tendency (controls, n = 50).
RESULTS: Cases were more frequently affected by hemophilia B than by hemophilia A, and showed a lower incidence of severe FVIII/FIX gene defects (referred to as null mutations), higher FVIII and FIX antigen levels and higher ETP values in platelet-rich plasma than controls (P < 0.05). By multivariate logistic regression, only non-null mutations were confirmed as an independent predictor of a mild clinical phenotype.
CONCLUSIONS: These results indicate that non-null mutations represent the main determinant of the bleeding tendency, and that ETP measurement in platelet-rich plasma is able to identify severe hemophiliacs with a mild clinical phenotype.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20102490     DOI: 10.1111/j.1538-7836.2010.03767.x

Source DB:  PubMed          Journal:  J Thromb Haemost        ISSN: 1538-7836            Impact factor:   5.824


  42 in total

1.  Prophylaxis for adults with haemophilia: one size does not fit all.

Authors:  Kathelijn Fischer
Journal:  Blood Transfus       Date:  2012-04       Impact factor: 3.443

2.  Outcome in moderate haemophilia: back to the past? Remarks on haemophilia A classification and treatment.

Authors:  Giuseppe Tagariello; Paolo Radossi; Giancarlo Castaman
Journal:  Blood Transfus       Date:  2013-04-18       Impact factor: 3.443

Review 3.  Genomics of bleeding disorders.

Authors:  A C Goodeve; A Pavlova; J Oldenburg
Journal:  Haemophilia       Date:  2014-05       Impact factor: 4.287

4.  Recombinant long-acting glycoPEGylated factor IX in hemophilia B: a multinational randomized phase 3 trial.

Authors:  Peter W Collins; Guy Young; Karin Knobe; Faraizah Abdul Karim; Pantep Angchaisuksiri; Claus Banner; Türkiz Gürsel; Johnny Mahlangu; Tadashi Matsushita; Eveline P Mauser-Bunschoten; Johannes Oldenburg; Christopher E Walsh; Claude Negrier
Journal:  Blood       Date:  2014-09-26       Impact factor: 22.113

5.  An RNAi therapeutic targeting antithrombin to rebalance the coagulation system and promote hemostasis in hemophilia.

Authors:  Alfica Sehgal; Scott Barros; Lacramioara Ivanciu; Brian Cooley; June Qin; Tim Racie; Julia Hettinger; Mary Carioto; Yongfeng Jiang; Josh Brodsky; Harsha Prabhala; Xuemei Zhang; Husain Attarwala; Renta Hutabarat; Don Foster; Stuart Milstein; Klaus Charisse; Satya Kuchimanchi; Martin A Maier; Lubo Nechev; Pachamuthu Kandasamy; Alexander V Kel'in; Jayaprakash K Nair; Kallanthottathil G Rajeev; Muthiah Manoharan; Rachel Meyers; Benny Sorensen; Amy R Simon; Yesim Dargaud; Claude Negrier; Rodney M Camire; Akin Akinc
Journal:  Nat Med       Date:  2015-04-13       Impact factor: 53.440

Review 6.  Position paper on laboratory testing for patients with haemophilia. A consensus document from SISET, AICE, SIBioC and SIPMeL.

Authors:  Armando Tripodi; Rita C Santoro; Sophie Testa; Angelo C Molinari; Sergio Bernardini; Maria Golato; Giuseppe Lippi; Walter Ageno; Elena Santagostino
Journal:  Blood Transfus       Date:  2019-02-04       Impact factor: 3.443

7.  Recombinant factor VIIa addition to haemophilic blood perfused over collagen/tissue factor can sufficiently bypass the factor IXa/VIIIa defect to rescue fibrin generation.

Authors:  R Li; K A Panckeri; P F Fogarty; A Cuker; S L Diamond
Journal:  Haemophilia       Date:  2017-05-05       Impact factor: 4.287

8.  Proposal for standardized preanalytical and analytical conditions for measuring thrombin generation in hemophilia: communication from the SSC of the ISTH.

Authors:  Y Dargaud; A S Wolberg; E Gray; C Negrier; H C Hemker
Journal:  J Thromb Haemost       Date:  2017-06-28       Impact factor: 5.824

Review 9.  Thrombin generation and whole blood viscoelastic assays in the management of hemophilia: current state of art and future perspectives.

Authors:  Guy Young; Benny Sørensen; Yesim Dargaud; Claude Negrier; Kathleen Brummel-Ziedins; Nigel S Key
Journal:  Blood       Date:  2013-01-14       Impact factor: 22.113

10.  Specific and global coagulation tests in patients with mild haemophilia A with a double mutation (Glu113Asp, Arg593Cys).

Authors:  Alenka Trampuš Bakija; Maruša Debeljak; Irena Preložnik Zupan; Majda Benedik Dolničar; Jernej Kovač; Janez Jazbec
Journal:  Blood Transfus       Date:  2015-05-15       Impact factor: 3.443

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.